Announcement PDF BIOME AUSTRALIA · ASX: BIO 1 1 Biome Australia FY26 RESULTS & COMPANY PRESENTATION Biome Australia Australia’s #1 fastest-growing probiotic brand — clinically-backed, profitable, and scaling. September 2026 ASX: BIO The Microbiome Health Company Biome Australia Group Our mission To prevent disease, improve health outcomes and quality of life, and make our products accessible to all BIOME AUSTRALIA · ASX: BIO 3 3 Biome Australia INVESTMENT HIGHLIGHTS Profitable, clinically-differentiated, and scaling Biome develops, owns and clinically validates proprietary probiotic strains, sold through pharmacy and practitioner channels under the Activated Probiotics® and Activated Therapeutics® brands. Australia’s #1 fastest-growing probiotic brand Leader by revenue in community pharmacy, with 100% of the range in growth. A record, profitable year FY26 delivered record revenue of $23.9m, up 30%, building on FY25’s first full-year net profit. Clinically differentiated 30+ randomised controlled trials, plus a proprietary strain — BMB18 — now in a 240-participant human trial. Scaling at home and abroad ~7,500 points of sale and four international markets live, tracking to the Vision 2027 plan. BIOME AUSTRALIA · ASX: BIO 4 4 Biome Australia OUR JOURNEY From start-up to Australia’s fastest-growing probiotic brand Revenue has compounded at ~75% a year from FY20 to FY26, with FY26 a record full year. FY20 $830k First full year of sales → FY26 $23.9m Revenue, +30% year on year Clinically-backed range Built on 30+ randomised controlled trials. Scaled distribution From a standing start to ~7,500 points of sale across pharmacy. Profitable and compounding Ten consecutive EBITDA-positive quarters. International reach Live in five markets, with international revenue of $1.8m in FY26. BIOME AUSTRALIA · ASX: BIO 5 5 Biome Australia FY26 FINANCIAL SCORECARD Record results across every key metric REVENUE $23.9m +30% vs FY25 ADJUSTED EBITDA $2.0m +115% vs FY25 NET PROFIT (PRE-TAX) $1.2m +453% vs FY25 GROSS MARGIN 62.1% +1pp vs FY25: 61.1% OPERATING CASH FLOW $1.6m FY25: $2.9m (outflow) EPS 1.62 cents FY25: 0.10 cents BIOME AUSTRALIA · ASX: BIO 6 6 Biome Australia OPERATING LEVERAGE Earnings growing far faster than revenue +30% Revenue growth (PCP) +453% Net profit (pre-tax) growth (PCP) Profit is compounding more than four times faster than revenue — with gross margin increased to 62.1% and tenth consecutive EBITDA-positive quarter. BIOME AUSTRALIA · ASX: BIO 7 7 Biome Australia REVENUE TRAJECTORY Compounding revenue, now profitable FY26 $23.9m Revenue · +30% on FY25 $2.0m Adj EBITDA (excl SBP) FY26 — Second full-year net profit. Ten straight EBITDA-positive quarters. FY20 to FY26 actual full-year revenue. BIOME AUSTRALIA · ASX: BIO 8 8 Biome Australia FY27 PRIORITIES The path to success for FY27 (execution of Vision 27) The platform is built and profitable. FY27 is about converting it to scale, focusing on key priorities: Onshore manufacturing & margin Onshore production starts this month with Specialty Probiotics Australia (SPA) agreement — underpinning the 65%+ margin outlook. China launch Exclusive cross-border e-commerce agreement signed with H&S Global; Activated Probiotics launch planned within FY27. BMB18 clinical trial The 240-participant trial with La Trobe University, underway since February 2026, is targeted to read out in FY27. International conversion Four markets are built and staffed — FY27 is about conversion and depth, in addition to new entry in China. Vision 27 close-out The final year of the three-year plan — 8,000 points of sale, $75m cumulative sales (FY25–FY27). FY27 priorities are management plans, not guidance, and remain subject to execution, scale-up and the risks set out in this presentation. BIOME AUSTRALIA · ASX: BIO 9 9 Biome Australia MANUFACTURING & MARGIN Onshoring manufacturing — margin and working-capital upside A binding supply & purchase agreement brings key manufacturing onshore — structurally lifting gross margin and releasing working capital. Gross-margin uplift Increasing significantly from the strong 62.1% today commencing from FY27 Working-capital release A shorter, local supply chain will free up significant capital tied up in inventory, goods-in-transit and shortens the cash-conversion cycle. Supply security & Australian-made Onshore production reduces lead times and import dependency — aligned with Biome’s B Corp credentials. The milestone Binding agreement was executed on June 2 2026; first onshore production from September 2026. BIOME AUSTRALIA · ASX: BIO 10 10 Biome Australia MARGIN BENCHMARK Gross margin against the businesses acquirers just bought Every business below was acquired in the past twelve months, except Life-Space. Margins are as last reported by each. Biome 65%+ stated outlook 65.0% Biome Australia FY26 reported 62.1% Life-Space Group CY17 60.0% Thorne FY22 50.2% Jamieson Wellness FY25 41.2% Biome converts a dollar of revenue into more gross profit than any of them.Jamieson and Thorne both manufacture in-house; Life-Space and Biome outsource. Jamieson FY2025, computed from quarterly releases. Thorne FY2022, its last full year listed. Life-Space per By-Health Shenzhen Stock Exchange filings at acquisition. Biome 62.1% as reported for FY26; the 65%+ figure is the outlook announced 3 June 2026, subject to commercial scale-up, and is not a reported result. BIOME AUSTRALIA · ASX: BIO 11 11 Biome Australia MARKET OPPORTUNITY A large market — significant growth headroom Global probiotics market ~US$75bn+ growing 7–9% p.a. Australian probiotics market ~A$600m Biome today ~$24m* ← significant headroom We hold a low-single-digit share of our home market today — with 7,500-store distribution and five international markets still to convert. *Annualised on H1 FY26 revenue. Market sizes are management estimates. BIOME AUSTRALIA · ASX: BIO 12 12 Biome Australia MARKET POSITION Fastest-growing brand in pharmacy’s biggest VMS category (FY26) #1 Probiotic Products in Pharmacy Biome Daily #1, Brand the highest growth in the category, all products in growth #2 Terry White Chemmart Second-largest brand by revenue in professional vitamins category and #1 for growth in largest pharmacy chain in Australia. #1 Priceline Pharmacy Growth #1 Sales growth (+36%) and 5th brand for profit in category. #1 Wholesale category growth (Symbion / API) 100% of the range in growth. BIOME AUSTRALIA · ASX: BIO 13 13 Biome Australia HOW WE WIN Practitioner Only - High Value - Solution driven Practitioner endorsement drives full-margin growth 1 Practitioner education → 2 Clinical recommendation → 3 Pharmacy purchase → 4 Scan data validates → 5 Category leadership A pull model. Demand is created by clinical recommendation and validated by scan data — full-margin growth, without promotional discounting. BIOME AUSTRALIA · ASX: BIO 14 14 Biome Australia PRODUCT PLATFORM Two clinically-backed brand families The clinical moat competitors can’t replicate Activated Probiotics® Condition-specific, practitioner-recommended probiotics across the range. Activated Therapeutics® Selective, clinically-validated formulations for targeted applications. • Practitioner-Only • 30+ randomised controlled trials on Biome’s finished products. • Peer-reviewed publication, including in The Lancet. • Evidence across mood & sleep, immune & respiratory, skin, bone, cholesterol and children’s health. • Hard to replicate — trials take years and capital and earn the practitioner trust that drives the pull model. BIOME AUSTRALIA · ASX: BIO 15 15 Biome Australia CLINICAL EVIDENCE The clinical moat competitors can’t replicate • 30+ randomised controlled trials on Biome’s finished products. • Peer-reviewed publication, including in The Lancet. • Evidence across mood & sleep, immune & respiratory, skin, bone, cholesterol and children’s health. • Practitioner-Only • Hard to replicate — trials take years and capital, and earn the practitioner trust that drives the pull model. BIOME AUSTRALIA · ASX: BIO 16 16 Biome Australia LEAD ASSET — BMB18 A proprietary strain in human clinical trial BMB18 — Probiotic · 100% Biome-owned · DSM registered • In-vitro results: immune modulation, oxidative-stress reduction, gut-barrier integrity. • 240-participant, double-blind, placebo-controlled RCT with La Trobe University; commenced February 2026 (ANZCTR registered). • Sits on an existing base of 30+ RCTs across Biome’s finished products. BIOME AUSTRALIA · ASX: BIO 17 17 Biome Australia DISTRIBUTION From 100 to a 7,500-store footprint ~7,500 Points of sale by end FY26 ~12,000 Addressable AU locations 8,000 FY27 target (Vision 27) Progress to the Vision 27 distribution target Started at 100 stores 8,000 by FY27 Distribution has grown from 100 to over 7,000 points of sale, laddering toward the Vision 27 target of 8,000 by FY27 — with roughly 12,000 addressable. BIOME AUSTRALIA · ASX: BIO 18 18 Biome Australia INTERNATIONAL Four markets past proof point FY26 international performance. Practitioner-only and clinically backed in every market. $1.8m FY26 int'l revenue +20% on FY25 ~68% Int'l gross margin 6ppabove domestic ~2,000 Distribution points andgrowing rapidly 12 International FTE across four markets ≈ B/E Approaching breakeven $1.8m revenue vs$1.82 opex Where the revenue comes from Canada Fullscript and Ecotrend Largest international contributor United Kingdom Wholesale, marketing and distribution Northern Ireland hub serves the EU Ireland Uniphar and Green Cross 1,989 practitioner touchpoints New Zealand ProPharma and Green Cross NZ$2.3bn addressable, ~1,100 points First mover in a category where every other brand sells online and through discounters. Four markets are live, staffed and contributing, with the build phase behind us. FY26 international figures are unaudited. Breakeven measured as international revenue against international operating expense. BIOME AUSTRALIA · ASX: BIO 19 19 Biome Australia PRICING POWER International earns a premium, and holds it One global pricing architecture. Biome Daily anchors a premium, non-discounted position in every market. AUSTRALIA A$34.95 Home market RRP CANADA C$46.99 Fullscript / retail, ex tax UNITED KINGDOM £29.95 Practitioner RRP IRELAND €36.95 Uniphar retail NEW ZEALAND NZ$39.95 ProPharma RRP Every offshore market prices above the Australian home RRP in AUD-equivalent terms. Gross margin, domestic against international Domestic 62% International 68% Channel mix, not pricing International revenue weights toward practitioner-led, recommendation-driven sales, where shelf, banner and promotion overhead are absent. Growth was volume-led FY26 group growth came entirely from volume, with blended average selling price held flat year on year. No promotional erosion of brand equity. Biome Daily recommended retail price per market. Prices include local taxes except Canada, shown ex tax. Domestic and international margin split is estimated. Margin achieved in FY26 and not a forward expectation. BIOME AUSTRALIA · ASX: BIO 20 20 Biome Australia FY27 OUTLOOK What scales it from here The platform, people and channels are in place. FY27 is about conversion and depth, not new market entry. Canada Quebec market unlock and continued account growth with Fullscript and Ecotrend. United Kingdom Banner conversion and launch of the B2B2C practitioner platform in H1 FY27. Ireland Pharmacy expansion via Uniphar and their owned banners. New Zealand ProPharma, Pacific Health and Nutriscript Two structural changes behind them Onshore manufacturing Australian production commences September 2026 under the Specialty Probiotics Australia agreement. Small batch agility, faster and more efficient supply, premium finish and lower COGS for international scale. Northern Ireland as an EU gateway The Northern Ireland hub sits inside the UK and reaches mainland Europe directly, serving the UK alongside it. FY27 priorities are management plans and are not guidance. Onshore manufacturing commencement is subject to commercial scale-up. BIOME AUSTRALIA · ASX: BIO 21 21 Biome Australia CHINA The world’s second largest nutraceutical market US$17bn China's online nutraceutical market in 2025, growing 14% a year ~US$105bn of goods imported into China through cross border e-commerce in 2025 ~40% of China's supplement market is held by imported brands Probiotics sit in the top four supplement categories in China Behind fish oil, calcium and multivitamins Cross border sales of probiotics alone were around US$566m in 2025, growing 20% a year. No Blue Hat registration Products on the cross border positive list, legally marketed at home, sell direct to Chinese consumers with no reformulation. No capital expenditure The partner funds in-market operations and platform activity. Biome supplies finished goods. The buyer has changed. Chinese platforms are moving from celebrity and influencer endorsement toward healthcare professional engagement (KOL), and consumers are now asking about strain specificity and benefits beyond gut health. That is the problem Activated Probiotics was built to solve. Online nutraceutical market value, probiotics category ranking and probiotics cross border e-commerce value presented at Probiota Americas, June 2026. Cross border e-commerce import value derived from General Administration of Customs data for 2025, total cross border trade of RMB 2.75 trillion with exports above RMB 2 trillion. Imported share ofthe supplement market is a third party estimate. Regulatory position as at the date of this presentation. BIOME AUSTRALIA · ASX: BIO 22 22 Biome Australia CHINA Exclusive distribution partnership with H&S Global Heads of agreement signed for exclusive sales, marketing and distribution of the Activated Probiotics range in China throughcross border e- commerce. KEY TERMS Channel Cross border e-commerce Exclusivity 1-3 years from launch (subject to agreedvolumes) Products Activated Probiotics range, unchanged Launch Planned within FY27 Marketing Biome maintains control Brand and IP Retained in full by Biome Why now Australian manufacture Provenance is what this channel rewards most. The Specialty Probiotics Australia agreement brings production onshore from September 2026. A market that now asks for evidence Around 90% of gut health probiotics on Tmall compete on dose above 10 billion CFU,and 72% on nine or more strains. We compete on whether the strain and dose on the pack were the ones trialled. The right operator H&S Global was selected after a structured assessment of cross border operators. No China specific range. Chinese consumers get the same Australian made products Australians already buy, including the number one probiotic product in Australian pharmacy. Heads of agreement only. Completion is subject to execution of a definitive distribution agreement, agreement of volumes, minimum performance conditions and the launch date, and cross border e-commerce product compliance. No revenue target, volume commitment or earnings contribution is provided. Refer to the ASX announcement of [ ]2026. BIOME AUSTRALIA · ASX: BIO 23 23 Biome Australia CHINA What goes into the market The proposition is access to the products Australians are already buying, with the clinical work behind them. #1 Flagship daily probiotic Biome Daily The number one probiotic product in Australian pharmacy #1 Children's immune health Biome Daily Kids The number one immune health probiotic in Australian pharmacy Source: IQVIA pharmacy scan sales, July 2026. The credentials that travel Trialled at the strain and dose on pack Randomised, double blind, placebo controlled research on the finished product, not on the ingredient in general. Guaranteed to end of shelf life Strain level labelling with a CFU count guaranteed to expiry rather than at time of manufacture. A proprietary strain BMB18, registered with DSMZ in Germany, patent filed, human trial underway at La Trobe and Harokopio. Price integrity Not sold through grocery or discount pharmacy. The premium position holds in market. BMB18 clinical trial is in progress and results are not yet available. Australian Register of Therapeutic Goods listings apply to products supplied in Australia. BIOME AUSTRALIA · ASX: BIO 24 24 Biome Australia VISION 2027 The roadmap to FY27 FY25 DELIVERED • First net profit ($214,656) • Revenue $18.4m, +41.6% • International sales +69% • ~7,000 points of sale → FY26 DELIVERED • Revenue $23.9m, +30% • Adj. EBITDA $2.0m; 10th consecutive EBITDA+ quarter • Biome Daily #1 probiotic in AU pharmacy • ~7,500 points of sale; China HoA signed → FY27 TARGET • Vision 27: $75m cumulative sales (FY25–FY27) • 8,000 points of sale • International markets scaling • BMB18 clinical trial readout BIOME AUSTRALIA · ASX: BIO 25 25 Biome Australia INVESTMENT CASE Why Biome Category leader #1 fastest-growing probiotic brand in Australia’s biggest pharmacy category. Premium-margin model 62.1% gross margin, sustained without promotional discounting. Operating leverage proven Second consecutive net profit; ten consecutive EBITDA-positive quarters. Proprietary IP pipeline BMB18 in human trial; 30+ RCTs across the range. International optionality Four international markets live, revenue up 20%. China signed for FY27 launch. Fully-funded growth Cash-generative and largely self- funding the plan to Vision 27. BIOME AUSTRALIA · ASX: BIO 26 26 Biome Australia SECTOR CONTEXT What acquirers are paying for evidence-led brands Three transactions in the vitamins, minerals and supplements category announced since April 2026, with Life-Space for context. Target Acquirer Transaction value EV/ revenue Gross margin Growth Thorne Procter & Gamble US$3.8bn 7.6x 50.2% +30% Grüns Unilever ~US$1.2bn ~4.0x n/d n/d Jamieson Wellness Kirin Holdings C$2.5bn 3.0x 41.2% +11% Life-Space Group By-Health A$670m 6.8x ~60% +54% Life-Space, the closest structural comparable, was an Australian probiotics brand selling through pharmacy and Chinese cross border e-commerce at a gross margin of approximately 60%. By-Health paid A$670m. Sources: Jamieson Wellness / Kirin Holdings announcement 6 August 2026, FY25 revenue C$822.1m. Procter & Gamble / Thorne announcement 4 August 2026, 2025 revenue reported by CNBC as above US$500m. Unilever / Grüns announced April 2026 and completed 1 June 2026, transaction value not disclosed, press reports approximately US$1.2bn on approximately US$300m of revenue. By-Health / Life-Space Group signed 31 January 2018, completed September 2018, final consideration approximately A$670m per By-Health Shenzhen Stock Exchange filings. Multiples are on last reported revenue at announcement and are shown for sector context only. This page is not a valuation of Biome Australia and no inference should be drawn as to the value of Biome shares. BIOME AUSTRALIA · ASX: BIO 27 27 Biome Australia CAPITAL STRUCTURE Snapshot & balance sheet ASX code BIO Share price 36.5c Market capitalisation $83.2m Shares on issue 228m Performance rights / options Nil Cash (FY26 Close) $3.6m Debt drawn (FY26 Close) $1.9m Undrawn facility $3.1m 52-week range 20c – 53c BALANCE SHEET Net cash position, no dilution overhang $3.6m cash against $1.9m drawn — with a further $3.1m undrawn and no options or performance rights on issue. TOP SHAREHOLDERS Founder, management & staff 13% Board 4% High-net-worth investors 3.5% - 5% Institutional funds 2.0% - 4.99% Top 50 holders 57% Share price andmarket capitalisation as at 11 September 2026; registeras at 1June 2026; cash anddebt as at 30June 2026. BIOME AUSTRALIA · ASX: BIO 28 28 Biome Australia THANK YOU Profitable. Clinical. Scaling. Blair Vega Norfolk · Founder & Managing Director Lauren Dwyer · Chief Financial Officer corporate@biomeaustralia.com biomeaustralia.com · activatedprobiotics.com.au ASX: BIO Certified B Corporation. BIOME AUSTRALIA · ASX: BIO 29 29 Biome Australia DISCLAIMER This presentation and the information contained within it (the “information”) has been prepared solely for the use and benefit of the person to whom it is provided (the “recipient”). It has been provided to the recipient on a strictly confidential basis solely for the purpose of assisting the recipient to determine whether it may be interested in participating in the investment opportunity described in this presentation (“Opportunity”) and if so, to participate in that process, and may only be used for that purpose. This presentation contains selected information only and does not purport to contain all of the information that may be relevant to the Opportunity. The information is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. This presentation has not been filed, registered or approved in any jurisdiction. The information is provided for general information purposes only, without taking into account any person’s objectives, financial situation or needs. It should not be relied on by the recipient in considering the merits of any particular transaction, including the Opportunity. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment of the contents of the Information. Past performance information included in this presentation is provided for illustrative purposes only, should not be relied upon and is not an indication of future performance. Biome Australia Limited (“Company”) and its related bodies corporate, directors, officers, partners, employees, advisers, consultants and agents make no representation nor give any warranty, express or implied, as to the accuracy, completeness, reliability, timeliness or suitability of the information or that the information may be used in any given way or to achieve any given result. This presentation contains forward-looking statements, which may be identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’ or ‘intends’ and other similar words that connote risks and uncertainties. Certain statements, beliefs, and opinions contained in this presentation, in particular those regarding the possible or assumed future financial or other performance, industry growth or other trend projections are predictions only, and not guarantees, and subject to inherent risks and uncertainties. Except to the extent required by law, none of the Company, its Related Persons or any other person gives any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur and investors are cautioned not to place undue reliance on such forward-looking statements. A summary of the key risks associated with the Company, its business and an investment in its shares is set out at the end of this presentation. All forward- looking statements are subject to risk factors, many of which are beyond the control of the Company and its Related Persons and, if they were to occur, could cause the Company’s actual financial results to differ materially from the results expressed or anticipated in the forward-looking statements. The information should be read in conjunction with the risk factors set out at the end of this presentation. The information is based on an assessment of the economic and operating conditions as at the date of this presentation, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Except to the extent required by law, the Company and its Related Parties will not be updating or revising the information. The recipient must, and agrees with the Company that it will, make its own independent assessment of the accuracy, completeness, reliability, timeliness and suitability of the information and its own determination of whether the information is appropriate to be used for any given purpose. The recipient will rely upon the information at its own risk. To the maximum extent permitted by law, the Company and its Related Persons exclude and disclaim all liability for any loss, damage, cost or expense suffered by the recipient or any other person arising from or in connection with use or reliance on (in any manner) the information or the recipient’s participation in the Opportunity, whether the loss, damage, cost or expense arise because of negligence, default, misrepresentation or some other cause, and whether or not foreseeable. To the maximum extent permitted by law, the recipient (on its own behalf and on behalf of each of its representatives) unconditionally and irrevocably releases the Company and its Related Persons from all claims and liability. The Company holds this release for itself and on trust for its Related Persons. The information contained in this presentation represents the Company’s strategy as determined by the board of directors as at the date of this presentation (14 September 2026), and the board reserves its right to change this strategy and conduct the business of the Company as appropriate having regard to changes in market or operating conditions.